Eylea HD (aflibercept) injection 8 mg sBLA accepted for FDA priority review for both the treatment of macular oedema following retinal vein occlusion and for monthly dosing in approved indications

Regeneron Pharmaceuticals

17 April 2025 - If approved, Eylea HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated for all other anti-VEGF therapies.

Regeneron Pharmaceuticals today announced that the US FDA has accepted for priority review the supplemental biologics license application for Eylea HD (aflibercept) Injection 8 mg.

Read Regeneron Pharmaceuticals press release 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Dossier